(redirected from Well-Differentiated Neuroendocrine Tumors)
WDNTWell-Differentiated Neuroendocrine Tumors
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
There is very limited literature that observes the outcomes of CAPTEM as treatment for well-differentiated neuroendocrine tumors. Table 3 summarizes the current data on CAPTEM in NETs.
KC et al., "Comparison of the prognostic values of [sup.68]Ga-DOTANOC PET/CT and [sup.18]F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor," European Journal of Nuclear Medicine and Molecular Imaging, vol.
Perren, "The problem of high-grade gastroenteropancreatic neuroendocrine neoplasms: well-differentiated neuroendocrine tumors, neuroendocrine carcinomas, and beyond," Endocrinology and Metabolism Clinics of North America, vol.
Useful Immunomarkers for Site of Origin of Metastatic Well-Differentiated Neuroendocrine Tumors (NETs) Marker Likely Site of Comment Origin TTF-1 Lung Relatively low sensitivity.
Just adjacent to the CCPRCC, a microscopically separate 1.5 cm well-differentiated neuroendocrine tumor was identified focally invading the hilar fat (Figure 3).
[5], found that diverticulosis was present in 23 patients (1.7%) of a series of 1361 cases, of which 11 harbored appendiceal neoplasm, including 5 well-differentiated neuroendocrine tumors (carcinoid), 3 mucinous adenomas, 2 mucinous adenocarcinomas, and 1 tubular adenoma.
Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
While well-differentiated neuroendocrine tumor or well-differentiated neuroendocrine neoplasm is now the preferred term for tumors of gastrointestinal tract and the pancreas, (30) carcinoid tumor, particularly of the appendiceal primary, remains a time-honored diagnosis both in pathology reports and in the literature.
Well-differentiated neuroendocrine tumors (carcinoid tumors) were first characterized in 1907 by Siegfried Oberndorfer, (1) a German pathologist who coined the term karzinoide, or "carcinoma-like." The recognition of their endocrine-related properties was later described by Gosset and Masson (2) in 1914.
This protocol applies to well-differentiated neuroendocrine tumors of the appendix.
This protocol applies to well-differentiated neuroendocrine tumors of the duodenum, ampulla, jejunum, and ileum.
Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors).
Full browser ?